Wave Life Sciences Ltd. (WVE)
Automate Your Wheel Strategy on WVE
With Tiblio's Option Bot, you can configure your own wheel strategy including WVE - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol WVE
- Rev/Share 0.5729
- Book/Share 0.8973
- PB 10.2646
- Debt/Equity 0.1476
- CurrentRatio 2.5576
- ROIC -0.8291
- MktCap 1465679400.0
- FreeCF/Share -1.2203
- PFCF -7.3241
- PE -11.6292
- Debt/Assets 0.086
- DivYield 0
- ROE -0.7753
- Rating C-
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 1
- P/B Score 1
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | WVE | Canaccord Genuity | -- | Buy | -- | $19 | Aug. 4, 2025 |
| Initiation | WVE | Oppenheimer | -- | Outperform | -- | $24 | July 28, 2025 |
| Initiation | WVE | Citigroup | -- | Buy | -- | $16 | July 16, 2025 |
| Resumed | WVE | Raymond James | -- | Outperform | -- | $14 | June 11, 2025 |
| Initiation | WVE | Cantor Fitzgerald | -- | Overweight | -- | $10 | April 29, 2025 |
| Initiation | WVE | Wedbush | -- | Outperform | -- | $18 | April 8, 2025 |
| Initiation | WVE | Jefferies | -- | Buy | -- | $26 | Feb. 25, 2025 |
| Upgrade | WVE | Raymond James | Outperform | Strong Buy | -- | $22 | Oct. 16, 2024 |
| Resumed | WVE | JP Morgan | -- | Overweight | $10 | $13 | Sept. 27, 2024 |
| Initiation | WVE | B. Riley Securities | -- | Buy | -- | $11 | Sept. 19, 2024 |
News
Wave Life Sciences (WVE) Reports Q2 Loss, Misses Revenue Estimates
Published: July 30, 2025 by: Zacks Investment Research
Sentiment: Negative
Wave Life Sciences (WVE) came out with a quarterly loss of $0.31 per share versus the Zacks Consensus Estimate of a loss of $0.29. This compares to a loss of $0.25 per share a year ago.
Read More
Wave Life Sciences Reports Second Quarter 2025 Financial Results and Provides Business Update
Published: July 30, 2025 by: GlobeNewsWire
Sentiment: Neutral
WVE-006, the leading GalNAc-RNA editing oligonucleotide designed to correct AAT protein and address both lung and liver manifestations of AATD, rapidly advancing in RestorAATion-2 study of AATD patients; multi-dosing is complete in first cohort (200 mg) and single dosing is complete in second cohort (400 mg)
Read More
Wave Life Sciences Announces Oral Presentation of Preclinical Data Supporting WVE-007's Mechanism (INHBE) to Reduce Fat, Preserve Muscle, and Induce Healthy Weight Loss at ADA's Annual Scientific Sessions
Published: June 20, 2025 by: GlobeNewsWire
Sentiment: Neutral
Presentation to highlight WVE-007 (INHBE GalNAc-siRNA) as a potential novel and unique obesity treatment leading to healthy weight loss and supporting preclinical data demonstrating potent and durable reduction in Activin E resulting in fat loss with muscle preservation
Read More
Wave Life Sciences (WVE) Reports Q1 Loss, Lags Revenue Estimates
Published: May 08, 2025 by: Zacks Investment Research
Sentiment: Negative
Wave Life Sciences (WVE) came out with a quarterly loss of $0.29 per share versus the Zacks Consensus Estimate of a loss of $0.27. This compares to loss of $0.24 per share a year ago.
Read More
Wave Life Sciences Reports First Quarter 2025 Financial Results and Provides Business Update
Published: May 08, 2025 by: GlobeNewsWire
Sentiment: Neutral
Dosing complete in the first two cohorts of INLIGHT trial in obesity of WVE-007 (INHBE siRNA), designed to induce healthy weight loss by reducing fat without impacting muscle; clinical data on track for 2H 2025 Dosing underway in second single dose cohort (400 mg) and multidosing (200 mg) ongoing in RestorAATion-2 clinical trial of WVE-006 in individuals with PiZZ AATD; data from the complete 200 mg multidose and single dose cohorts expected in 3Q 2025; data from complete 400 mg single dose cohort expected in the fall of 2025 Delivered positive data from FORWARD-53 clinical trial of WVE-N531 in exon …
Read More
Analysts Estimate Wave Life Sciences (WVE) to Report a Decline in Earnings: What to Look Out for
Published: May 01, 2025 by: Zacks Investment Research
Sentiment: Negative
Wave Life Sciences (WVE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Read More
Wave Life Sciences First Quarter 2025 Financial Results Scheduled for May 8, 2025
Published: May 01, 2025 by: GlobeNewsWire
Sentiment: Neutral
CAMBRIDGE, Mass., May 01, 2025 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, will host a live webcast and conference call at 8:30 a.m. ET on Thursday, May 8, 2025, to review the company's first quarter 2025 financial results and provide business updates.
Read More
Promising Genomics & Synthetic Biology Stocks to Consider in 2025
Published: March 28, 2025 by: Zacks Investment Research
Sentiment: Positive
Investors interested in the Genomics and Synthetic Biology theme should consider these stocks: Twist Bioscience Corporation, Wave Life Sciences, and CRISPR Therapeutics AG.
Read More
About Wave Life Sciences Ltd. (WVE)
- IPO Date 2015-11-11
- Website https://www.wavelifesciences.com
- Industry Biotechnology
- CEO Paul B. Bolno
- Employees 287